Navigation Links
Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
Date:9/14/2007

DUBLIN, Ohio, Sept. 14 /PRNewswire-FirstCall/ -- In advance of its annual investor meeting, Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, reaffirmed its earnings-per-share (EPS) target for the fiscal year and updated the profit outlook for its operating segments.

The company said non-GAAP EPS from continuing operations(1) is still expected to exceed the long-term goal of 12 to 16 percent growth it set in June, finishing the year in a range of $3.95 to $4.15 per share.

To reflect an industry-wide moderation in the sale of prescription drugs, the company revised the outlook for its Supply Chain Pharmaceutical segment, which is now expected to grow profit during the year in line with its long-term goal of 7 to 10 percent growth. Cardinal Health previously said profit growth for this segment was expected at the top end of the long-term range.

Financial targets remain unchanged for the company's three other operating segments.

"While market factors led us to revise our outlook for the Supply Chain Pharma segment, the strength of our Clinical and Medical Products businesses allow us to maintain our EPS guidance range for the full year," said R. Kerry Clark, chief executive officer of Cardinal Health. "The diversity of our portfolio is a key differentiator, offering stable growth and strong cash flow in our core supply chain services sector, and faster growth with higher returns in our clinical and medical products sector."

The company will host its annual meeting for invited investment professionals and financial analysts on Sept. 19 in New York. More information about the meeting may be found on the investor page of http://www.cardinalhealth.com.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE:

SOURCE Cardinal Health
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cardinal Calls For Legal Response Against Da Vinci Code
2. Poor health care in Russia maybe causing Decline in its Population
3. Startling Expose – Physicians Often Have No Regular Source Of Health Car
4. Debate Rages over firing of HIV infected health care workers
5. Want a Healthy brew? Have some Tea!
6. Patient’s perception of health status helps in better recover
7. Antioxidants protect health tissue in people undergoing radiation therapy.
8. Sexual abuse affect health for a lifetime
9. Smoking a greater risk than HIV? Yes say health experts!!!!
10. Healthcare sector is now a multi billion-dollar industry in India
11. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...r University Medical Center at Dallas and the Bayl...introduce insulin genes into the pancreas//. Ins... sugar) to enter the cells of the body to be used ...ltrasound-targeted micro bubble destruction (UTMD)...
...uota issue between government and striking medicos...ing with their demand of setting up an experts com...riking medicos are also expected to meet Union Hea...r in the day. The resident doctors association of...
...ug Administration authority is under pressure as i...rug as an over-the counter drug//. Andrew von Esc...rged to take an independent, non-biased decision o...d to sell its morning after pill or Plan B without...
...ior doctors of Sir Sunderlal hospital in the Banar...unger strike// for the second consecutive day toda...a for the backward castes in the higher education ...nger strike, the agitating doctors formed human ch...
Other Medicine News:Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2
(Date:10/6/2008)... Annual Scientific Conference -, ORLANDO, Fla., O...rmerly Microbia) today announced presentation of d... the role that cyclic guanosine,monophosphate (cGM...dies,demonstrate that cGMP inhibits intestinal pai...a and desensitizes colonic afferent nerves in a,si...
(Date:10/6/2008)...MICADE Therapy is More Likely to Induce Steroid-...tandard Immunomodulator, Azath...ta presented for the first time,from the Phase 3b ...munomodulators and Biologic Therapy (SONIC) may pr...tients with moderate to severe Crohn,s disease.,Ac...
(Date:10/6/2008)...eristics of Naltrexone SR Associated with ...PHOENIX, Oct. 6 /- Orexigen...eutical company focused on the treatment of,obesit...rs, today presented,data showing the investigation...), successfully achieved key objectives (lowered n...
(Date:10/5/2008)...nd Journal of Medicine reaffirm,well-established e...,HandiHaler(R), RIDGEFIELD, Conn., and NEW YORK, ...rstanding Potential Long-term Impacts on Function ...diHaler(R) (tiotropium bromide,inhalation powder),... 4,years as measured by FEV(1) (p<0.001) versus pl...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Argosy publishing launches The Visible Body 13442 1Argosy publishing launches The Visible Body 13442 2Argosy publishing launches The Visible Body 13442 3Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 1Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 1Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 3Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 4Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 5New potential drug target for the treatment of atherosclerosis 13430 1New potential drug target for the treatment of atherosclerosis 13430 2New potential drug target for the treatment of atherosclerosis 13430 3
... -- Genotypically Optimized Dosing Results in Impr... -- , MELBOURNE, Australia, and MENLO PARK, Califo...s (ASX: CXS, NASDAQ: CXSP) announced,today the pre...ydrochloride) phase 1/2a dose-escalation study, de...of Quinamed in heavily,pre-treated patients with a...
... Data From the Companies, Novel Heat Shock Protein...olerability, and Biological,Activity , CAMBRIDGE, ...EWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq...ounced updated interim,results from a Phase I clin... (Hsp90) inhibitor, IPI-504, in patients with rela...
Other Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7
...tem will define the state of knee implants. Now, f... requirements and increasing surgical options, whi...ons. The GENESIS II femoral components meet these...tomeet todays surgical demands. Clinical issues su...
Cruciate retaining, posterior stabilized and constrained components.
...tmental total knee prosthesis stems from many year...he-art design and manufacturing technologies have ...l function as well as a favorable pressure distrib... keep wear to a minimum. The inherent design of th...
Offset Liners - Plus 5 mm Neutral
Medicine Products: